Distribution of SALT Scores with Ritlecitinib Treatment Up to 24 Months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

The study evaluated the long-term efficacy of ritlecitinib, a JAK3/TEC family kinase inhibitor, in treating alopecia areata over 24 months. It included 191 patients, with 27 adolescents and 164 adults, who received 50 mg of ritlecitinib daily. Results showed a reduction in patients with high Severity of Alopecia Tool (SALT) scores, indicating significant hair regrowth. At baseline, all participants had a SALT score of ≥50, with 71.2% having scores >90. By Month 24, only 14.2% remained in the SALT >90-100 category, while 50.8% achieved SALT scores of 0-10. The study concluded that ritlecitinib effectively reduces severe hair loss over time, providing valuable insights for clinicians in managing treatment expectations.